Terminated PHASE3 INTERVENTIONAL 2-arm NCT01439789

Study of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure Patients

A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Efficacy/Safety of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure

Sponsor: Zensun Sci. & Tech. Co., Ltd.

Conditions Chronic Heart Failure

Interventions Placebo rhNRG-1

Updated 6 times since 2017 Last updated: Dec 19, 2017 Started: Jun 30, 2011 Primary completion: Jun 30, 2012 Completion: Jun 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor has designed another study with different endpoint to replace the current study

Other terminated trials from Zensun Sci. & Tech. Co., Ltd.

More terminations from Zensun Sci. & Tech. Co., Ltd.

Other Chronic Heart Failure trials with similar outcome

Browse all Chronic Heart Failure trials

Listed as NCT01439789, this PHASE3 trial focuses on Chronic Heart Failure and remains terminated or withdrawn. Sponsored by Zensun Sci. & Tech. Co., Ltd., it has been updated 6 times since 2011, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Jan 2018 — Jun 2018 [monthly]

Terminated PHASE3

▶ Show 1 earlier version

Jan 2017 — Jan 2018 [monthly]

Terminated PHASE3

First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Zensun Sci. & Tech. Co., Ltd.

Data source: Zensun Sci. & Tech. Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changchun, China , Changsha, China , Chengdu, China , Chongqing, China , Dalian, China , Daqing, China , Haerbin, China , Jinan, China , Jinzhou, China and 9 more locations